Akoya Biosciences, Inc. (AKYA)

NASDAQ: AKYA · IEX Real-Time Price · USD
2.850
-0.050 (-1.72%)
At close: May 17, 2024, 4:00 PM
2.900
+0.050 (1.75%)
After-hours: May 17, 2024, 7:29 PM EDT
-1.72%
Market Cap 141.74M
Revenue (ttm) 93.57M
Net Income (ttm) -68.01M
Shares Out 49.39M
EPS (ttm) -1.45
PE Ratio n/a
Forward PE n/a
Dividend n/a
Ex-Dividend Date n/a
Volume 354,288
Open 2.920
Previous Close 2.900
Day's Range 2.770 - 2.970
52-Week Range 2.650 - 8.800
Beta 1.52
Analysts Strong Buy
Price Target 7.79 (+173.33%)
Earnings Date May 13, 2024

About AKYA

Akoya Biosciences, Inc., a life sciences technology company, provides spatial biology solutions focused on transforming discovery and clinical research in North America, the Asia Pacific, Europe, the Middle East, and Africa. The company offers PhenoCycler instrument, a compact bench-top fluidics system that integrates with a companion microscope to automate image acquisition; and PhenoImager platform that enables researchers to visualize, analyze, quantify, and phenotype cells in situ, in fresh frozen or FFPE tissue sections, and tissue microar... [Read more]

Sector Healthcare
IPO Date Apr 16, 2021
Employees 330
Stock Exchange NASDAQ
Ticker Symbol AKYA
Full Company Profile

Financial Performance

In 2023, AKYA's revenue was $96.63 million, an increase of 29.09% compared to the previous year's $74.86 million. Losses were -$63.32 million, -10.36% less than in 2022.

Financial Statements

Analyst Forecast

According to 8 analysts, the average rating for AKYA stock is "Strong Buy." The 12-month stock price forecast is $7.79, which is an increase of 173.33% from the latest price.

Price Target
$7.79
(173.33% upside)
Analyst Consensus: Strong Buy
Stock Forecasts

News

Akoya Biosciences Reports First Quarter 2024 Financial Results

MARLBOROUGH, Mass., May 13, 2024 (GLOBE NEWSWIRE) -- Akoya Biosciences, Inc. (Nasdaq: AKYA) (“Akoya”), The Spatial Biology Company®, today announced its financial results for the first quarter ending ...

5 days ago - GlobeNewsWire

Akoya Biosciences and NeraCare Enter into an Exclusive Agreement to Enable Personalized Therapy Selection for Early-Stage Melanoma Patients

Leveraging Akoya's market-leading PhenoImager HT platform and clinical development expertise with NeraCare's Immunoprint test and best-in-class clinical data, the partnership will focus on increasing ...

9 days ago - GlobeNewsWire

Akoya Biosciences Opens Operations and Manufacturing Center of Excellence in Marlborough, Massachusetts

MARLBOROUGH, Mass., May 06, 2024 (GLOBE NEWSWIRE) -- Akoya Biosciences, Inc., (Nasdaq: AKYA), The Spatial Biology Company®, has opened its Operations and Manufacturing Center of Excellence in Marlboro...

12 days ago - GlobeNewsWire

Akoya Biosciences and Shanghai KR Pharmtech Announce Chinese Regulatory Agency Premarket Approval for KR-HT5 in China to Support Next Generation Pathology Clinical Workflows

MARLBOROUGH, Mass. and SHANGHAI, China, May 02, 2024 (GLOBE NEWSWIRE) -- Akoya Biosciences, Inc. (Nasdaq: AKYA), The Spatial Biology Company®, and Shanghai KR Pharmtech, a leading company providing mo...

16 days ago - GlobeNewsWire

Akoya to Report First Quarter 2024 Financial Results on May 13th, 2024

MARLBOROUGH, Mass., April 22, 2024 (GLOBE NEWSWIRE) -- Akoya Biosciences, Inc. (Nasdaq: AKYA) (“Akoya”), The Spatial Biology Company®, today announced that it will release financial results for the fi...

26 days ago - GlobeNewsWire

Akoya Biosciences Showcases Spatial Biology 2.0 Solutions at AACR Annual Meeting with Case Studies Demonstrating Unprecedented Speed and Scale

MARLBOROUGH, Mass., April 05, 2024 (GLOBE NEWSWIRE) -- Akoya Biosciences, Inc., (Nasdaq: AKYA), The Spatial Biology Company®, today announced it will highlight case studies featuring its Spatial Biolo...

6 weeks ago - GlobeNewsWire

Akoya Biosciences Names BostonGene as a Qualified CRO Service Provider

WALTHAM, Mass.--(BUSINESS WIRE)--BostonGene, a leading provider of AI-driven molecular and immune profiling solutions, announced today that it has been named as a qualified contract research organizat...

2 months ago - Business Wire

Akoya Reports Record Revenue in the Fourth Quarter of 2023 and Provides Full Year 2024 Financial Outlook

Q4 2023 revenue $26.5 million and FY 2023 revenue $96.6 million Guiding FY 2024 revenue range $114.0-118.0 million and operating cash flow breakeven by YE 2024

2 months ago - GlobeNewsWire

Akoya to Report Fourth Quarter and Full Year 2023 Financial Results on March 4th, 2024 and Participate at an Upcoming Investor Conference

MARLBOROUGH, Mass., Feb. 08, 2024 (GLOBE NEWSWIRE) -- Akoya Biosciences, Inc. (Nasdaq: AKYA) (“Akoya”), The Spatial Biology Company®, today announced that it will release financial results for the fou...

3 months ago - GlobeNewsWire

Akoya Biosciences' Technology Enables Queensland Spatial Biology Centre to Revolutionize the Diagnosis and Treatment of Cancer and Other Diseases

PhenoCycler®-Fusion system selected as the Centre's platform technology for advanced spatial biology studies PhenoCycler®-Fusion system selected as the Centre's platform technology for advanced spatia...

4 months ago - GlobeNewsWire

Akoya Biosciences Announces that Garry Nolan, Ph.D., James Allison, Ph.D.

Leading immunotherapy and immunobiology experts will offer strategic direction and expertise in translational, clinical, and diagnostic applications of Akoya's spatial biology solutions Leading immuno...

4 months ago - GlobeNewsWire

Akoya Biosciences Deploys the MaxFuse Algorithm Co-Developed by Dr. Garry Nolan and His Laboratory at Stanford University for Multiomic Integration of Spatial and Single-cell Data on the Enable Medicine Platform

MaxFuse enables matching and integration of datasets from spatial proteomics, spatial transcriptomics, single-cell sequencing, or other modalities

4 months ago - GlobeNewsWire

Akoya Biosciences Announces Preliminary Financial Results for the Fourth Quarter and Full Year 2023 and Provides 2024 Outlook

MARLBOROUGH, Mass., Jan. 07, 2024 (GLOBE NEWSWIRE) -- Akoya Biosciences, Inc. (Nasdaq: AKYA) (“Akoya”), The Spatial Biology Company®, today announced preliminary unaudited revenue for the fourth quart...

4 months ago - GlobeNewsWire

Akoya Biosciences and Thermo Fisher Scientific Announce a License and Distribution Agreement to Deliver Spatial Multiomics Workflow

The Thermo Fisher Scientific ViewRNA technology combined with Akoya's market leading spatial biology solutions will enable rapid, whole-slide imaging of RNA and protein biomarkers The Thermo Fisher Sc...

4 months ago - GlobeNewsWire

Akoya to Participate at 42nd Annual J.P. Morgan Healthcare Conference

MARLBOROUGH, Mass., Dec. 20, 2023 (GLOBE NEWSWIRE) -- Akoya Biosciences, Inc. (Nasdaq: AKYA) (“Akoya”), The Spatial Biology Company®, today announced that it will be participating in the 42nd Annual J...

5 months ago - GlobeNewsWire

Akoya Reports Record Revenue in the Third Quarter of 2023 and Reiterates Full Year 2023 Revenue Guidance

Q3 2023 revenue $25.2 million, 34% y/y growth Reiterating FY 2023 revenue guidance range of $95-98 million

6 months ago - GlobeNewsWire

Akoya to Participate at Three Upcoming Investor Conferences

MARLBOROUGH, Mass., Nov. 02, 2023 (GLOBE NEWSWIRE) -- Akoya Biosciences, Inc. (Nasdaq: AKYA) (“Akoya”), The Spatial Biology Company®, today announced that Company management will be participating in t...

7 months ago - GlobeNewsWire

Akoya Biosciences to Showcase New Spatial Biology 2.0 Solutions and Spatial Phenotyping Data at SITC 2023

Spatial Biology 2.0 solutions enable discovery and translational workflows at an unprecedented speed and scale Global network of CROs providing Akoya's spatial phenotyping solutions will also exhibit ...

7 months ago - GlobeNewsWire

Akoya Biosciences Announces Peer-Reviewed Publication Using Ultrahigh-Plex Spatial Phenotyping of Head and Neck Cancer to Identify Distinct Immune and Metabolic Signatures

MARLBOROUGH, Mass., Oct. 17, 2023 (GLOBE NEWSWIRE) -- Akoya Biosciences, Inc. (Nasdaq: AKYA) (“Akoya”), The Spatial Biology Company®, today announced that researchers from Akoya Biosciences and The Un...

7 months ago - GlobeNewsWire

Akoya to Report Third Quarter 2023 Financial Results on November 8th, 2023

MARLBOROUGH, Mass., Oct. 11, 2023 (GLOBE NEWSWIRE) -- Akoya Biosciences, Inc. (Nasdaq: AKYA) (“Akoya”), The Spatial Biology Company®, today announced that it will release financial results for the thi...

7 months ago - GlobeNewsWire

Akoya Biosciences Sets a New Standard for Scaling Spatial Biology with the Launch of 2.0 Platforms

MARLBOROUGH, Mass., Sept. 19, 2023 (GLOBE NEWSWIRE) -- Akoya Biosciences, Inc. (Nasdaq: AKYA) (“Akoya”), The Spatial Biology Company®, today highlighted the industry-leading scale and speed in whole-s...

8 months ago - GlobeNewsWire

Akoya Reports Record Revenue in the Second Quarter of 2023 and Reiterates Full Year 2023 Revenue Guidance

Q2 2023 revenue $23.5 million, 31% y/y growth Reiterating FY 2023 revenue guidance range of $95-98 million

10 months ago - GlobeNewsWire

Akoya Biosciences Announces Milestone of 1,000 Peer-Reviewed Publications Citing Use of its Spatial Biology Technologies

MARLBOROUGH, Mass., Aug. 07, 2023 (GLOBE NEWSWIRE) -- Akoya Biosciences , Inc. (Nasqad: AKYA)(“Akoya), The Spatial Biology Company®, today announced a momentous achievement - publication of the 1,000t...

10 months ago - GlobeNewsWire

Akoya to Report Second Quarter 2023 Financial Results on August 7th, 2023

MARLBOROUGH, Mass., July 12, 2023 (GLOBE NEWSWIRE) -- Akoya Biosciences, Inc. (Nasdaq: AKYA) (“Akoya”), The Spatial Biology Company®, today announced that it will release financial results for the sec...

11 months ago - GlobeNewsWire

Akoya to Participate at Two Upcoming Investor Conferences

MARLBOROUGH, Mass., June 12, 2023 (GLOBE NEWSWIRE) -- Akoya Biosciences, Inc. (Nasdaq: AKYA) (“Akoya”), The Spatial Biology Company®, today announced that Company management will be participating in t...

1 year ago - GlobeNewsWire